T46.6X5 Category · further specificity required Adverse effect of antihyperlipidemic and antiarteriosclerotic drugs
ICD-10-CM T46.6X5 identifies “Adverse effect of antihyperlipidemic and antiarteriosclerotic drugs” as a category requiring further specificity in the FY2027 U.S. classification, effective October 1, 2026 through September 30, 2027.
Chapter 19: Injury, poisoning and certain other consequences of external causes
Code-level instructions
No additional notes.
Inherited instructions
Chapters 19 · Injury, poisoning and certain other consequences of external causes (S00-T88)
Excludes 22
- birth trauma (P10-P15)
- obstetric trauma (O70-O71)
Use additional code1
code to identify any retained foreign body, if applicable (Z18.-)
Note2
- Use secondary code(s) from Chapter 20, External causes of morbidity, to indicate cause of injury. Codes within the T section that include the external cause do not require an additional external cause code
- The chapter uses the S-section for coding different types of injuries related to single body regions and the T-section to cover injuries to unspecified body regions as well as poisoning and certain other consequences of external causes.
T36-T50 · Poisoning by, adverse effects of and underdosing of drugs, medicaments and biological substances (T36-T50)
Includes4
- adverse effect of correct substance properly administered
- poisoning by overdose of substance
- poisoning by wrong substance given or taken in error
- underdosing by (inadvertently) (deliberately) taking less substance than prescribed or instructed
Excludes 11
toxic reaction to local anesthesia in pregnancy (O29.3-)
Excludes 25
Code first7
Use additional code4
Note1
The drug giving rise to the adverse effect should be identified by use of codes from categories T36-T50 with fifth or sixth character 5.
T46 · Poisoning by, adverse effect of and underdosing of agents primarily affecting the cardiovascular system
Excludes 11
poisoning by, adverse effect of and underdosing of metaraminol (T44.4)
Seventh character1
The appropriate 7th character is to be added to each code from category T46
A — initial encounter
D — subsequent encounter
S — sequela
More specific codes
T46.6X5AAdverse effect of antihyperlipidemic and antiarteriosclerotic drugs, initial encounterBillable / specificT46.6X5DAdverse effect of antihyperlipidemic and antiarteriosclerotic drugs, subsequent encounterBillable / specificT46.6X5SAdverse effect of antihyperlipidemic and antiarteriosclerotic drugs, sequelaBillable / specificOfficial index references
Official index references (52)
Acipimox (1)
- AcipimoxDrugs and chemicals
Allyl (1)
- Allyl › disulfideDrugs and chemicals
Aluminium, aluminum (1)
- Aluminium, aluminum › clofibrateDrugs and chemicals
Antiarteriosclerotic drug (1)
- Antiarteriosclerotic drugDrugs and chemicals
Anticholesterolemic drug NEC (1)
- Anticholesterolemic drug NECDrugs and chemicals
Antihyperlipidemic drug (1)
- Antihyperlipidemic drugDrugs and chemicals
Antilipemic drug NEC (1)
- Antilipemic drug NECDrugs and chemicals
b-benzalbutyramide (1)
- b-benzalbutyramideDrugs and chemicals
b-sitosterol(s) (1)
- b-sitosterol(s)Drugs and chemicals
Benfluorex (1)
- BenfluorexDrugs and chemicals
Benzalbutyramide (1)
- BenzalbutyramideDrugs and chemicals
Benzyl (1)
- Benzyl › nicotinateDrugs and chemicals
Bezafibrate (1)
- BezafibrateDrugs and chemicals
Binifibrate (1)
- BinifibrateDrugs and chemicals
Cholesterol-lowering agents (1)
- Cholesterol-lowering agentsDrugs and chemicals
Cholestyramine(resin) (1)
- Cholestyramine(resin)Drugs and chemicals
Ciprofibrate (1)
- CiprofibrateDrugs and chemicals
Clinofibrate (1)
- ClinofibrateDrugs and chemicals
Clofibrate (1)
- ClofibrateDrugs and chemicals
Clofibride (1)
- ClofibrideDrugs and chemicals
Clotibric acid (1)
- Clotibric acidDrugs and chemicals
Colestipol (1)
- ColestipolDrugs and chemicals
Colestyramine (1)
- ColestyramineDrugs and chemicals
Cyamopsis tetragonoloba (1)
- Cyamopsis tetragonolobaDrugs and chemicals
Detaxtran (1)
- DetaxtranDrugs and chemicals
Ethylparachlorophen-oxyisobutyrate (1)
- Ethylparachlorophen-oxyisobutyrateDrugs and chemicals
Etiroxate (1)
- EtiroxateDrugs and chemicals
Etofibrate (1)
- EtofibrateDrugs and chemicals
Etofylline (1)
- Etofylline › clofibrateDrugs and chemicals
Fenofibrate (1)
- FenofibrateDrugs and chemicals
Gemfibrozil (1)
- GemfibrozilDrugs and chemicals
Guar gum(medicinal) (1)
- Guar gum(medicinal)Drugs and chemicals
Halofenate (1)
- HalofenateDrugs and chemicals
Ion exchange resin (1)
- Ion exchange resin › cholestyramineDrugs and chemicals
Linoleic acid (1)
- Linoleic acidDrugs and chemicals
Linolenic acid (1)
- Linolenic acidDrugs and chemicals
Lovastatin (1)
- LovastatinDrugs and chemicals
Mesoglycan (1)
- MesoglycanDrugs and chemicals
Oleic acid (1)
- Oleic acidDrugs and chemicals
Pirozadil (1)
- PirozadilDrugs and chemicals
Polidexide(sulfate) (1)
- Polidexide(sulfate)Drugs and chemicals
Pravastatin (1)
- PravastatinDrugs and chemicals
Probucol (1)
- ProbucolDrugs and chemicals
Ronifibrate (1)
- RonifibrateDrugs and chemicals
Safflower oil (1)
- Safflower oilDrugs and chemicals
Simfibrate (1)
- SimfibrateDrugs and chemicals
Simvastatin (1)
- SimvastatinDrugs and chemicals
Sitosterols (1)
- SitosterolsDrugs and chemicals
Soysterol (1)
- SoysterolDrugs and chemicals
Sunflower seed oil (1)
- Sunflower seed oilDrugs and chemicals
Triparanol (1)
- TriparanolDrugs and chemicals
Unsaturated fatty acid (1)
- Unsaturated fatty acidDrugs and chemicals
History
Code history
Latest recorded change · FY2025 · 04-01
Effective from
- Inherited rules changed
Adverse effect of antihyperlipidemic and antiarteriosclerotic drugs
Category — select a more specific code
CDC/NCHS · FY2025 · 04-01All editions (19)
| All editions | Effective from | Code history |
|---|---|---|
| FY2016 | 2015-10-01 | First observed |
| FY2017 | 2016-10-01 | No tabular change |
| FY2018 | 2017-10-01 | No tabular change |
| FY2019 | 2018-10-01 | Inherited rules changed |
| FY2020 | 2019-10-01 | No tabular change |
| FY2020 · April | 2020-04-01 | No tabular change |
| FY2021 | 2020-10-01 | Inherited rules changed |
| FY2021 · 01-01 | 2021-01-01 | No tabular change |
| FY2022 | 2021-10-01 | No tabular change |
| FY2022 · 04-01 | 2022-04-01 | No tabular change |
| FY2023 | 2022-10-01 | No tabular change |
| FY2023 · 04-01 | 2023-04-01 | No tabular change |
| FY2024 | 2023-10-01 | No tabular change |
| FY2024 · 04-01 | 2024-04-01 | No tabular change |
| FY2025 | 2024-10-01 | No tabular change |
| FY2025 · 04-01 | 2025-04-01 | Inherited rules changed |
| FY2026 | 2025-10-01 | No tabular change |
| FY2026 · April | 2026-04-01 | No tabular change |
| FY2027 | 2026-10-01 | No tabular change |
Explore the more specific codes in this category. Reference checks do not establish clinical appropriateness or guarantee reimbursement.